Background The sensitization and exposure to fungal allergens have been reported to be associated with asthma. The aim of this study was to clarify the impact of sensitization to Schizophyllum commune (S. commune) on the severity and exacerbations of asthma. Methods Ninety-two patients with asthma of various levels of severity [mild (n = 18), moderate (28), and severe (46)] and exacerbation severity [moderate (n = 43) and severe (6)] were retrospectively examined with regard to fungal sensitization such as specific IgE or intradermal skin reactions against S. commune and other common allergens. We also classified the patients into three groups: (1) three or more asthma attacks during the past year (F-BA) (n = 29),(2) one or two asthma attacks (NF-BA) (n = 20), and (3) no asthma attack (C-BA) (n = 43).
Introduction
Throughout the Global Initiative for Asthma (GINA) Science Committee report in 2009 [1] , emphasis is placed on the concept that the goal of asthma treatment is to achieve and maintain clinical control. Each asthmatic patient should be assessed to establish his/her level of asthma control according to the five items of clinical manifestations, and then assigned to one of five ''treatment steps'' in accordance with the management approach based on the level of asthma control. Furthermore, as an assessment of future risk, frequent exacerbations in the past year are listed as the features that are associated with an increased risk of adverse events in the future. Because patients with well-controlled asthma are less likely to experience exacerbations than those whose asthma is not well-controlled, preventing any exacerbation of asthma is an important clinical issue in asthma control.
It is well-known that fungal exposure is associated with exacerbations. Recently, the sensitization and exposure to fungal allergens such as Aspergillus, Alternaria, Penicillium, Cladosporium, and Trichophyton have been reported to be associated with asthma exacerbations and severity [2] , and the frequency of exacerbations, treatment requirements, and admission to intensive care for asthma has been found to be associated with skin-test reactivity to one or more fungi [3] . Thus, the investigations to identify environmental fungi are considered to be part of the initial assessment to enable the use of avoidance strategies in asthma management [4] .
From the results of our series of studies [5, 6] on patients with allergic fungal respiratory diseases, we have focused on the possible role of basidiomycetous (BM) fungi, especially Bjerkandera adusta [7] (B. adusta, the major cause of ''allergic fungal cough'' in Japan), as a fungal aeroallergen [8] . We recently encountered two cases of asthma caused by Schizophyllum commune (S. commune, ''suehirotake'' in Japanese) [9] . Although this fungus, one of the BM fungi, is well-known as a causative fungus of mucoid impaction of the bronchi (MIB) [10] , allergic bronchopulmonary mycosis (ABPM) [11, 12] , and allergic fungal sinusitis (AFS) [13] , the influence of sensitization to the fungus in asthmatics has not yet been reported. Therefore, we compared the allergological findings of asthmatics and reported the impact of sensitization to S. commune on the severity and the exacerbations of asthma.
Materials and Methods
The medical records of 92 patients with asthma, who were referred to Saiseikai Kanazawa Hospital between August and October 2009 and who had not been treated with maintenance oral corticosteroids, were collected and reviewed retrospectively. In this study, the severity of asthma in the patients had been already classified based on their clinical features and lung function in accordance with the 2006 GINA guidelines [14] ; this previous classification was recommended only for research purposes by GINA 2009. Asthma exacerbation severity was classified according to the recent recommended definitions provided by the Task Force [15] , wherein ''severe exacerbations'' are events that usually require hospitalization/emergency room (ER) visits and/or the use of systemic corticosteroids for at least 3 days (acute care settings), and ''moderate exacerbation'' is as an event that leads to an increase in the need for existing asthma therapy not including systemic corticosteroids, or a change in asthma symptoms/lung function over a period of at least 2 days not warranting hospital admission (community settings).
Because the classification of the frequency of exacerbation has not yet been clearly defined, we classified the patients who had experienced exacerbations requiring intravenous corticosteroid therapies despite adequate interval control into three groups according to the frequency of the episodes as an assessment of exacerbation tendency: (1) patients who had experienced exacerbations three or more times during the past year (frequent group, F-BA), (2) patients who had experienced one or two exacerbations (nonfrequent group, NF-BA), and (3) patients who had never experienced such exacerbations (controlled group, C-BA).
The following information was collected from the medical records of all patients: name, date of birth, gender, smoking habits, and the results of examinations such as blood tests, chest radiographs, and pulmonary function tests. For the measurements of allergic status, the allergological tests such as intradermal skin test and serological test had been performed at least 3 months after the latest exacerbation. Patients with asthma of each severity, each exacerbation severity, and each exacerbation frequency were compared in a cross-sectional manner with regard to gender, age, FEV 1 , and allergological characteristics.
This retrospective study was approved by the Institutional Review Board (reference number 2009004), and written informed consent was obtained from each of the 92 patients.
Preparation of the Antigenic Solution
The antigens Aspergillus, Alternaria, and Candida were commercially available (Torii Pharmacy, Tokyo, Japan). One liter of Sabouraud dextrose broth in 3 l flasks was sterilized. Five milliliters of a B. adusta (NBRC 4983) or S. commune spore suspension (10 5 spores/ml) in sterile physiological saline from 14-day-old Sabouraud dextrose agar culture was used to inoculate the flask. The flask was shaken at 150 rpm in a 25°C rotary shaker incubator for 14 days. Mycelia were separated by filtration and centrifuged. The supernatants were dialyzed against 5 mM ammonium bicarbonate and lyophilized.
Allergological Tests

Intradermal Skin Test
An antigenic solution (polysaccharide) was injected intradermally with a tuberculin syringe (0.02 ml, 1 mg/ml) to assess the skin response to the solution. The results were judged to be positive when the longer axis of the flare exceeded 9 mm at 15 min (immediate phase) and 10 mm at 8 h (late phase) after the injection. The results of the late skin test were checked and recorded by each patient at 8 h after the tests. The next day we telephoned the patients and completed the examination.
Serological Test
House-dust, mite, Aspergillus, Alternaria, Penicillium, Cladosporium, Candida Trichophyton: Allergen-specific IgE antibodies were detected using a capsulated hydrophilic carrier polymer radioallergosorbent test fluoroenzyme immunoassay (Phadia, Uppsala, Sweden) at an external laboratory (SRL, Tokyo, Japan).
Schizophyllum commune: The Phadia (formerly Pharmacia) CAP system was used to quantify specific IgE levels [16] . A positive test was a measurement [0.35 unit of allergen (UA)/ml.
Statistical Analysis
Variables are expressed as the mean (SD) unless otherwise stated. For comparison of multiple groups, analysis of variance (ANOVA) followed by a Fisher protected leastsignificant-difference post-hoc test was used for parametric data when significant difference was found. For nonparametric data, the Kruskal-Wallis test followed by the Mann-Whitney U test was applied instead. The v 2 test was used for categorical data. Logistic regression analysis was performed to test for independent effects of age, smoking habit, lung functions, and positive late-phase skin reactions against S. commune on asthma severity and exacerbation severity. Multiple-regression analysis was performed on exacerbation frequency. Analyses were performed using StatView (SAS Institute; Cary, NC). A P value of \ 0.05 was considered statistically significant.
Results
The clinical records of 92 asthmatics were gathered and analyzed. Chest and sinus radiographs were normal in all patients. The results of the late-phase positive skin reaction tests were obtained from 57, 72, and 57 patients for Aspergillus, S. commune, and B. adusta, respectively.
Analysis for Asthma Severity (Table 1)   Table 1 shows the characteristics and results of the three groups of asthma severity. Patients with mild and moderate severities of asthma were significantly younger than the patients with severe asthma. The smoking habits did not differ among the groups. The FVC (% predicted), FEV 1 (% predicted), and FEV 1 /FVC ratio (%) in mild and moderate asthmatics were significantly higher than those in severe asthmatics (P \ 0.05, P \ 0.01, and P \ 0.01, respectively). The total IgE levels and the positive rate for a specific IgE did not differ among the groups.
The positive skin reaction rates did not differ among the groups except for the late-phase skin reaction against S. commune (P \ 0.05). The results of an investigation of the serum S. commune-specific IgE levels were available for 12 patients and the value was not elevated in any of them.
A multiple logistic regression analysis was performed by including age and late-phase skin reaction against S. commune as possible predictors of asthma severity. The probability of severe versus mild or moderate asthma was found to be significantly associated with age and positive late-phase skin reaction against S. commune (Table 4) .
Analysis for Exacerbation Severity (Table 2) In this analysis, 43 patients who had never experienced any exacerbations were excluded. Table 2 gives the characteristics and results of the other two groups defined by their exacerbation severity. The two groups were well matched by gender and age. Current smoker was predominant in the severe exacerbation group. The FVC (% predicted) and FEV 1 (% predicted) in the moderate exacerbation group were significantly higher than those in the severe exacerbation group.
The number of patients from whom we had obtained the results of the late-phase positive skin reaction tests for each fungus is given in Table 2 . The positive late-phase skin reaction against S. commune (83.3%) was significantly higher in the severe exacerbation group than in the moderate exacerbation group (P \ 0.01).
A multiple logistic regression analysis was performed by including smoking habits, lung functions, and the latephase skin reaction against S. commune as possible predictors of exacerbation severity. The probability of the severe versus moderate exacerbation was not demonstrated in this analysis (Table 4) . (Table 3)   Table 3 gives the characteristics and results of three groups defined based on their exacerbation frequency. The age distribution, gender of the population, and smoking habits did not differ significantly among the three groups. The FVC (% predicted) and FEV 1 /FVC ratio (%) in the C-BA and NF-BA groups were significantly higher than those in the F-BA group (P \ 0.05 and P \ 0.01, respectively). The total IgE levels and the rate of positive specific IgE did
Analysis for Exacerbation Frequency
not differ significantly among the three groups. The rate of positive skin reactions did not differ among the groups except for the late-phase skin reaction against S. commune (P \ 0.001). Because %FVC and late skin reaction against S. commune were adopted as possible predictors of the exacerbation frequency according to a stepwise analysis among the three items, thereafter multiple logistic analyses were performed by including the two variables except the FEV 1 /FVC ratio (%). The probability of asthma exacerbation frequency was found to be significantly associated with %FVC and positive late-phase skin reaction against S. commune (P \ 0.0001) on the basis of a multiple regression analysis (Table 4) .
Discussion
Bronchial asthma is a chronic inflammatory disease of the airways, which may worsen due to numerous extrinsic factors such as continuous exposure to fungal agents. The factors that influence the risk of asthma have been divided into those that cause the development of asthma and those that trigger asthma symptoms. It is known that fungi involved in outdoor allergens are important as environmental factors, and our recent studies suggested that S. commune is an important candidate organism acting as a causative fungal antigen of bronchial asthma [9] , similar to the Trichophyton species [17] [18] [19] [20] . Therefore, we retrospectively examined whether an environmental fungus such as S. commune could enhance the clinical expression of asthma. Asthma severity has recently been classified on the basis of the intensity of treatment required to achieve good asthma control in subjects with ''mild asthma'' and ''severe asthma.'' The patient's asthma severity will be established based on a combination of their current level of symptoms and their current maintenance treatment step in future studies; however, in this retrospective study, the severity of all asthmatics had been classified based on their daily medication regimen and response to treatment, as described in the GINA 2006 guidelines for research purposes [1] . Matsuoka et al. [19] reported a strong association of the allergen with the severity of asthma and the establishment of sensitization using serum radioallergosorbent assays for IgE antibodies to Trichophyton. In contrast to their report, our present results demonstrated no association of serum specific IgE antibodies to Trichophyton with the severity of asthma. The presence of Trichophyton infection has been suggested to be an important determinant of sensitization to Trichophyton; however, in our study, there were no significant differences in the frequencies of fungal skin infections among the asthma severities. Therefore, it is impossible that fungal skin infections may affect the detection frequency of specific IgE against Trichophyton in our study. The present study revealed that there were no significant differences in the positive results for the immediate and late cutaneous reactions to three wellknown environmental fungi (Aspergillus, Alternaria, and Candida) among the asthma severities [21] . The reason for this result is unclear, but it might be related to geographic differences in the frequency of sensitization.
Asthma exacerbations are considered to be caused by a variety of factors such as allergens, viral infections, pollutants, drugs, and also fungi. Therefore, reducing a patient's exposure to risk factors will improve the control of their asthma and reduce their need for medication [22] . Each patient was assigned to one of five treatment steps depending on their current level of control, and treatment was adjusted in a continuous cycle that involved assessing asthma control, treating to achieve control, and monitoring to maintain control, and by changes in their asthma control [15] . Our current study revealed a significant difference in the smoking habit, lung function, and rate of positive late-phase skin reactions against S. commune, but the probability of the severe versus moderate exacerbation was not demonstrated based on multiple-regression analysis, thus suggesting that many other factors may be associated with the variability in the severity of exacerbation. In the GINA 2009, a history of frequent exacerbations in the preceding year was emphasized with respect to assessment of future risk and was listed as one of the features that were associated with an increased risk of adverse events in the future. The severity of each asthma attack, which reflects exacerbation rather than just transient loss of asthma control, may be affected by the magnitude of the response against viral infection or by the some other factors such as physical condition or severe weather. We therefore assumed that the so-called ''exacerbation tendency'' of asthma was represented by the frequency of exacerbations rather than by the severity of each exacerbation.
A multivariate analysis identified positive results for latephase skin reactions to S. commune and age as independent determinants of asthma severity, and skin results and %FVC as those of exacerbation frequency, but such a trend was not found for other allergens such as house-dust, Aspergillus, Alternaria, Penicillium, and Cladosporium [23] .
There is emerging evidence that the innate immune response in asthma is impaired, airway inflammation may modulate the response to triggers, and genetic polymorphisms may confer an increased risk of exacerbations [24] . Because it has been already suggested that the presence of eosinophilic inflammation in the bronchial wall promotes the development of exacerbation in combination with a viral infection, a clinical research study concerning the eosinophil response in the bronchial wall to S. commune or to the secretory products of this fungus will also be important to elucidate the mechanisms underlying the exacerbation of asthma in the future.
From the results of the present study, S. commune, a BM fungus, is considered to be one of the environmental fungi that have a potential role in enhancing the severity of asthma and asthma exacerbation via sensitization to the fungus. S. commune colonizes rotting wood and is distributed throughout the A multiple logistic regression analysis was performed by including age and the late-phase skin reaction against S. commune as possible predictors of asthma severity. It was also performed by including smoking habits, lung functions, and the late-phase skin reaction against S. commune as possible predictors of exacerbation severity. Because the %FVC and late skin reaction against S. commune were adopted as possible predictors of the exacerbation frequency according to a stepwise analysis among the three items, thereafter multiple logistic analyses were performed by including the two variables except FEV 1 /FVC ratio (%)
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world. Therefore, not only pharmacologic intervention [25, 26] but also careful environmental management [12] may positively help to prevent the development of asthma, asthma symptoms, and asthma exacerbations by either reducing or eradicating such antigen exposure.
